ArticlePsychiatry and clinical psychopharmacology2024
Successful Use of High-Dose Brexpiprazole for Psychosis in Lewy Body Dementia without Adverse Effects.
Article in Psychiatry and clinical psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Update on Parkinson's Disease Psychosis: Epidemiology, Mechanisms and Management.Neurology and therapy · 2026Review
- Treatment-resistant Parkinson's disease psychosis responding to xanomeline-trospium: A case report.Clinical parkinsonism & related disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Low doses of brexpiprazole (0.5-2 mg per day) have been tried to treat dementia-related psychosis/agitation and Parkinson's disease psychosis. We report a 71-year-old patient with a diagnosis of probable dementia with Lewy body (DLB) whose psychotic symptoms benefit from a higher dose of brexpiprazole (4 mg per day) without adverse effects. Though more studies were needed to confirm the safety and efficacy of brexpiprazole in the treatment of DLB, this case suggests that brexpiprazole is a potential treatment choice and it is safe even at the maximum daily dose (i.e., 4 mg per day).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.